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Objective To assess whether the benefit of highly active antiretroviral therapies (HAART) is continuing, a
longitudinal retrospective study of CD4 counts and viral load (VL) in a large group of human
immunodeficiency virus (HIV)-infected subjects was undertaken in Madrid.
Methods Consecutive plasma VL values and CD4þ T-lymphocyte counts were collected during a 3-month
period yearly from 1996 to 2000 in one HIV/acquired immune deficiency syndrome (AIDS) reference
institution, where currently around 1500 HIV-infected individuals are on regular follow-up.
Results VL values and CD4þ counts were collected at each time-point from an average of 375 and 391
patients, respectively. The proportion of subjects receiving HAART among those on any kind of
antiretroviral treatment increased between 1996 (61%) and 2000 (95.1%) (P< 0.01). The number of subjects
with undetectable VL (<500 HIV-RNA copies/mL) increased from 12% in 1996 to 64% in 2000 (P< 0.01).
Accordingly, the proportion of individuals with CD4þ counts >500 cells/mL increased from 16% in 1997
to 54% in 2000 (P< 0.01). Notably, the number of subjects with VL values >10 000 copies/mL has
declined over time, and currently represents only 17% of the population. Despite this favorable trend,
the proportion of subjects with low CD4þ counts (<200 cells/mL) seems to have reached a plateau,
in the range of 10%.
Conclusions A dramatic virological and immunological benefit has followed the introduction of HAART
in HIV-infected patients since 1996. This favorable trend seems to be maintained over time, despite the
negative impact of drug-related toxicity and/or adherence issues. However, a subgroup of subjects seems
to persist with low CD4 counts despite having good virological control. They should be managed with
alternative treatment strategies, including immune stimulatory agents.
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INTRODUCTION
The use of highly active antiretroviral therapies (HAART) in
human immunodeficiency virus (HIV)-infected patients results
in a significant reduction in plasma viral load (VL) and increases
in CD4þ T-lymphocyte counts. These two parameters are
independently associated with a slower HIV disease progression
[1,2]. As a result, the asymptomatic period and survival of HIV-
infected persons have extended significantly during the last 4
years [1,3–6]. However, some authors have recently noticed a
rebound in the number of deaths among their cohort of HIV-
infected patients [7], suggesting that the benefit of antiretroviral
therapy is no longer maintained in a subgroup of patients.
Drug-related toxicities and/or adherence issues could be the
major determinants of this drawback.
In Spain, HAART became widely used in 1997, and the
number of patients on this treatment has increased over time.
Accordingly, the number of cases of acquired immune defi-
ciency syndrome (AIDS) has declined dramatically [8], and
recent reports have indicated an increase in the average CD4þ
lymphocyte counts as well as a reduction in mean plasma VL
values in HIV populations [9]. However, concern exists over the
negative impact of issues such as poor adherence to treatment
(and further drug resistance) or the development of side-effects,
which could limit a sustained benefit of treatment [10–12].
To assess whether the benefit of HAART is continuing, a
longitudinal retrospective study of CD4 counts and VL values in
a large group of HIV-infected subjects was undertaken in
Madrid.
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PATIENTS AND METHODS
Demographics, CD4 counts and VL values were recorded from
patients attending the outpatient clinic of one HIV/AIDS
reference institution located in Madrid, where 1550 HIV-
infected individuals are currently on regular follow-up. The
patients are seen in the clinic every 3–4 months on a regular
basis. Different 3-month time-points were selected for each year
covering a 5-year period, from 1996 to 2000. Data were
obtained from the outpatients who attended the clinic con-
secutively during these years. The time-point for 1996 was the
first trimester, when the use of protease inhibitors was still not
available. Time-points for 1997–99 were the third trimester of
each year, whereas for 2000 the time-point was the first
trimester.
The number of patients on antiretroviral therapy for each
period and the proportion of those on three or more drugs were
recorded. If data from one patient were recorded more than
once during the same year, only the first visit was considered.
Occasionally, either VL values or CD4 counts were not available
for a given subject. The definition of HAARTwas restricted to
subjects being on at least three antiretroviral drugs, including at
least two nucleoside analogs and either one protease inhibitor or
one non-nucleoside reverse transcriptase inhibitor.
Plasma VL was quantified using the second-generation
bDNA assay (Bayer, Barcelona, Spain), following the manu-
facturer’s instructions [13]. This has a detection limit of 500
copies of HIV-RNA. CD4 counts were measured using a flow
cytometer (Coulter, Barcelona, Spain).
Statistical analyses
The results are reported as numbers and percentages. Compar-
isons between mean values were made using the SSPS 98
software. The comparison between categorical variables was
performed using the w2 test.
RESULTS
Table 1 summarizes the number of patients on antiretroviral
therapy (ART), and the proportion of these on HAART. Plasma
VL values were available for 193, 250, 355, 484 and 592
individuals at each year time-point, whereas CD4 counts were
recorded from 256, 250, 363, 482 and 606 patients at each time
interval.
The proportion of patients receiving HAART among those
with some ART increased from 1997 (61%) to 1999 (94.5%)
(P< 0.01), and this high proportion of patients on HAARTwas
maintained during the first trimester of 2000 (95.1%) (Table 1).
The most frequent drug combinations at the different time-
points were stavudine (d4T), lamivudine (3TC) and indinavir in
1996 and 1997; d4T, 3TC and nelfinavir in 1998; d4T, dida-
nosine (ddI) and nevirapine in 1999; and d4T, ddI and efavirenz
in 2000.
The proportion of subjects with undetectable VL
(<500 HIV-RNA copies/mL) increased from 12% in the first
trimester of 1996 to 64% in the first trimester of 2000 (P< 0.01)
(Figure 1). In addition, individuals with VL values above 10 000
copies/mL have declined over time, and currently represent
only 17% of the full outpatient clinic population.
In accordance with the benefit obtained in VL values through
the years, an increase in the proportion of patients with CD4þ
counts above 500 cells/mL has been noticed since 1996 (16%) up
to 2000 (54%) (P< 0.01) (Figure 1). This trend was not due to a
recent inclusion of more naı¨ve individuals with high CD4
counts (data not shown). Despite this fact, a plateau in the
proportion of subjects with low CD4þ T-cell counts
(<200 cells/mL) has been maintained over the last years, which
represents around 10% of individuals. This subgroup of patients
with low CD4 counts had a mean VL of 3458 HIV-RNA
Table1 Number of patients on antiretroviral therapy (ART) and its modality over time
1996 1997 1998 1999 2000
Patients on follow-up 706 906 1098 1328 1497
Patients on ART 422 700 944 1018 1186
(%) (59.7) (77.2) (85.9) (76.6) (79.2)
Patients on3 drugs 0 427 815 963 1129
(% in respect to the total of treated subjects) (0) (61) (86.3) (94.5) (95.1)
Figure 1 Overall trends in plasma HIV-RNA and CD4þ lymphocyte counts
in patients attending a clinical setting (from1996 to 2000).
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copies/mL and 35% of them had less than 500 HIV-RNA
copies/mL.
DISCUSSION
Previous reports have confirmed a dramatic virological and
immunological benefit in HIV-infected individuals following
the introduction of HAART [3,5,14,15]. However, difficulties
in adherence to multiple antiretroviral drugs for long per-
iods of time, the appearance of unexpected drug-related
side-effects, such as lipodystrophy or mitochondriopathies,
and/or the selection of drug-resistant viral variants might
compromise the long-term efficacy of antiretroviral therapy
[10–12,16].
Overall changes in mean CD4þ T cells and VL counts over
time in representative HIV populations provide a comprehen-
sive understanding of the global impact of antiretroviral therapy
[3,15]. Our results show a growing improvement in CD4þ T-
lymphocyte counts and VL values among HIV-infected out-
patients attending our institution since the introduction of
HAART. The proportion of subjects with undetectable plasma
viremia has increased up to 64%, and currently no more than
17% of subjects harbors VL values above 10 000 copies/mL.
This subgroup of subjects with detectable viremia consists
mainly of individuals at their first visit before beginning therapy,
as well as multiple ART-experienced persons, in which com-
plete suppression of HIV replication is no longer affordable with
the current antiretroviral drugs.
With respect to the immunological outcome, the proportion
of subjects with CD4þ lymphocyte counts higher than 500
cells/mL has increased from 12% in 1996 to 54% in 2000,
whereas the rate of those with fewer than 200 cells/mL has
decreased from 29% in 1996 to 10% in 2000. However, the
current number of subjects with CD4þ lymphocytes below 200
cells/mL seems to have reached a plateau. The discrepancy
between the favorable trends in virological and immunological
parameters needs to be interpreted cautiously. It has nothing to
do with the discordant response noticed in some individuals on
HAART who seem to respond well immunologically, despite
virological failure, as long as they continue on treatment. This
fact has been explained by the selection of viruses with a limited
replication capacity as a result of the accumulation of multiple
drug-resistant mutations [17,18]. Our observation concerns
populations rather than individuals, and suggests that a subgroup
of subjects might be unable to increase their CD4 counts above
a critical level (200 cells/mL) even when viral replication is
under good control on treatment. These individuals continue to
be at risk for opportunistic infections, and might be good
candidates for alternative therapeutic approaches, including
the use of immune stimulatory agents. Recent data suggest
that interleukin-2 might constitute an appropriate tool in this
subgroup of patients [19].
In summary, our data suggest that the virological and immu-
nological benefits provided by antiretroviral therapies seem to
persist over time. Overall, neither drug-related toxicity nor
adherence issues seem to have a negative impact on this favor-
able trend at a population level. However, a subgroup of subjects
(representing around 10% of the full population) seem to be
unable to increase their CD4 counts above 200 cells/mL, and
continue to be at risk for developing AIDS-defining events.
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